Novavax (NVAX) Tops Q3 EPS by 7c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $9.13 -3.89%
Revenue Growth %: -78.2%
Financial Fact:
Interest expense: -3.51M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: -78.2%
Financial Fact:
Interest expense: -3.51M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Novavax (NASDAQ: NVAX) reported Q3 EPS of ($0.76), $0.07 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $85 million versus the consensus estimate of $65.8 million.
GUIDANCE:
Novavax sees FY2024 revenue of $650-700 million, versus the consensus of $761.5 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kalshi in early talks for IPO - The Information
- Iran Says Hormuz To Close, Citing Ceasefire Violation- Tasnim
- Pfizer reaffirms 2026 guidance after CFO transition news
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
